- Home
- CNFR vs AIM Comparison
CNFR vs AIM Comparison
Compare CNFR & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- AIM
- Stock Information
- Founded
- CNFR 2009
- AIM 1966
- Country
- CNFR United States
- AIM United States
- Employees
- CNFR N/A
- AIM N/A
- Industry
- CNFR Property-Casualty Insurers
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNFR Finance
- AIM Health Care
- Exchange
- CNFR Nasdaq
- AIM Nasdaq
- Market Cap
- CNFR 14.2M
- AIM 15.9M
- IPO Year
- CNFR 2015
- AIM N/A
- Fundamental
- Price
- CNFR $1.11
- AIM $0.20
- Analyst Decision
- CNFR
- AIM Strong Buy
- Analyst Count
- CNFR 0
- AIM 2
- Target Price
- CNFR N/A
- AIM $2.75
- AVG Volume (30 Days)
- CNFR 15.0K
- AIM 403.8K
- Earning Date
- CNFR 11-13-2024
- AIM 11-15-2024
- Dividend Yield
- CNFR N/A
- AIM N/A
- EPS Growth
- CNFR N/A
- AIM N/A
- EPS
- CNFR 2.40
- AIM N/A
- Revenue
- CNFR $74,815,000.00
- AIM $190,000.00
- Revenue This Year
- CNFR N/A
- AIM N/A
- Revenue Next Year
- CNFR $7.00
- AIM $1,086.80
- P/E Ratio
- CNFR $0.44
- AIM N/A
- Revenue Growth
- CNFR N/A
- AIM N/A
- 52 Week Low
- CNFR $0.65
- AIM $0.16
- 52 Week High
- CNFR $1.91
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- CNFR 45.02
- AIM 40.44
- Support Level
- CNFR $1.06
- AIM $0.20
- Resistance Level
- CNFR $1.19
- AIM $0.23
- Average True Range (ATR)
- CNFR 0.08
- AIM 0.02
- MACD
- CNFR -0.00
- AIM 0.00
- Stochastic Oscillator
- CNFR 52.94
- AIM 10.75
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance company engaged in the sale of property and casualty insurance products. It is engaged in three classes of insurance businesses namely commercial lines, personal lines, and wholesale agency business. Within these three businesses, the company offers various insurance products and insurance agency services. The company views the commercial and personal lines segments as underwriting business. The wholesale agency business provides non-risk bearing revenue through commissions and policy fees. Its revenues are derived from premiums earned from insurance operations.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.